Navigation Links
AIDS Vaccine Failures Highlight Need to Focus on Lifesaving Treatment, Says AHF
Date:11/15/2007

As Vaccine Efforts Stumble, Millions Remain Without AIDS Treatment

Worldwide

LOS ANGELES, Nov. 15 /PRNewswire-USNewswire/ -- For the second time in two weeks, clinical researchers working to develop an AIDS vaccine have announced that their efforts have stumbled or, in the case of Merck -- outright failed -- after Merck's AIDS vaccine trial was halted last week when its vaccine was suspected of actually making some study participants more susceptible to contracting HIV. These latest shortcomings in the increasingly elusive search for a safe and effective AIDS vaccine underscore the need to focus on promoting HIV prevention and scaling up the delivery of lifesaving antiretroviral treatment (ART), both proven and existing strategies, to help keep people around the world from becoming infected, or for those already living with HIV/AIDS, alive and well, said AIDS Healthcare Foundation (AHF).

Earlier today, Reuters reported that " ... another experimental AIDS vaccine may damage the immune system by exhausting key cells ... a finding that may further cloud the field of HIV vaccines." Reuters noted that the researchers, who published their findings in the 'Journal of Clinical Investigation' said that, " ... vaccines using the viruses should not be tested on people until more studies are done," and that, " ... In mice, the adeno-associated virus, or AAV vaccines, directly interfered with immune cells called CD8 T-cells ... the 'killer' T-cells that a vaccine is supposed to muster to fight HIV."

"Development of a safe and effective AIDS vaccine is a clearly a noble and worthy goal; however, the sad truth remains that more than 40 million people worldwide are living with HIV/AIDS today, yet barely two million of them have access to lifesaving antiretroviral AIDS treatments," said Michael Weinstein, AIDS Healthcare Foundation President. "Treatments that actually do work and help keep those fortunate enough to have access to them alive and well. Treatments, which also have also been around, and continually improved, for over a decade. These recent failures in vaccine development underscore just how tenuous the quest for an AIDS vaccine remains, and reminds us of what effective, but underused tools, including antiretroviral treatment, we already have available to us today. While we long for the day when there is an effective preventive AIDS vaccine, we also call for a reevaluation of the distribution of limited government resources in the battle against AIDS, and renew our call for a greatly stepped-up worldwide commitment to bringing antiretroviral treatment to many, many more of those 38 million people still in need."

About AHF

AIDS Healthcare Foundation (AHF) is the US' largest non-profit HIV/AIDS healthcare, research, prevention and education provider. AHF currently provides medical care and/or services to more than 61,000 individuals in 18 countries worldwide in the US, Africa, Latin America/Caribbean and Asia. Additional information is available at http://www.aidshealth.org


'/>"/>
SOURCE AIDS Healthcare Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
3. Vaccine Stops Alzheimers Brain Tangles
4. Human Papilloma Virus vaccines may decrease chances of oral cancer
5. U.S. Teens Fall Short on Vaccine Coverage
6. Nasal Anthrax Vaccine Proves Effective in Animal Study
7. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
8. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
11. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  Commended for their devotion to personalized ... Ranked as number one in the South Florida Business Journal,s ... Inc. 5000 yearly list, the national specialty pharmacy has found ... Bardisa will soon be honored by SFBJ as the ... Set to receive his award in October, Bardisa ...
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology: